BTIG Reiterates Buy on Tvardi Therapeutics, Maintains $15 Price Target
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
BTIG analyst Julian Harrison reiterates Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and maintains $15 price target.
BTIG analyst Julian Harrison reiterates Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and maintains $15 price target.